SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Medizone International Inc – ‘10-K’ for 12/31/17 – ‘EX-10.23’

On:  Tuesday, 3/20/18, at 4:47pm ET   ·   For:  12/31/17   ·   Accession #:  1185185-18-468   ·   File #:  2-93277-D

Previous ‘10-K’:  ‘10-K’ on 3/22/17 for 12/31/16   ·   Latest ‘10-K’:  This Filing

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/20/18  Medizone International Inc        10-K       12/31/17   69:4.3M                                   Federal Filings, LLC/FA

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML    616K 
 2: EX-10.12    Material Contract                                   HTML     41K 
 3: EX-10.23    Material Contract                                   HTML     29K 
 4: EX-21       Subsidiaries List                                   HTML     18K 
 5: EX-31.1     Certification -- §302 - SOA'02                      HTML     28K 
 6: EX-31.2     Certification -- §302 - SOA'02                      HTML     27K 
 7: EX-32.1     Certification -- §906 - SOA'02                      HTML     22K 
 8: EX-32.2     Certification -- §906 - SOA'02                      HTML     22K 
15: R1          Document And Entity Information                     HTML     48K 
16: R2          Consolidated Balance Sheets                         HTML    102K 
17: R3          Consolidated Balance Sheets (Parentheticals)        HTML     32K 
18: R4          Consolidated Statements of Comprehensive Loss       HTML     59K 
19: R5          Consolidated Statements of Stockholders' Equity     HTML     62K 
                (Deficit)                                                        
20: R6          Consolidated Statements of Stockholders' Equity     HTML     28K 
                (Deficit) (Parentheticals)                                       
21: R7          Consolidated Statements of Cash Flows               HTML     95K 
22: R8          Note 1 - Organization and Summary of Significant    HTML     87K 
                Accounting Policies                                              
23: R9          Note 2 Inventory                                    HTML     23K 
24: R10         Note 3 - Trademark and Patents                      HTML     31K 
25: R11         Note 4 - Accounts Payable - Related Parties         HTML     23K 
26: R12         Note 5 - Accrued Expenses                           HTML     29K 
27: R13         Note 6 - Accrued Expenses - Related Parties         HTML     29K 
28: R14         Note 7 - Notes Payable                              HTML     38K 
29: R15         Note 8 - Notes Payable - Related Parties            HTML     24K 
30: R16         Note 9 - Warrant Liability                          HTML     33K 
31: R17         Note 10 - Commitments and Contingencies             HTML     40K 
32: R18         Note 11 - Equity Transactions                       HTML     65K 
33: R19         Note 12 - Going Concern                             HTML     27K 
34: R20         Note 13 - Subsequent Events                         HTML     29K 
35: R21         Accounting Policies, by Policy (Policies)           HTML    132K 
36: R22         Note 1 - Organization and Summary of Significant    HTML     54K 
                Accounting Policies (Tables)                                     
37: R23         Note 3 - Trademark and Patents (Tables)             HTML     31K 
38: R24         Note 5 - Accrued Expenses (Tables)                  HTML     28K 
39: R25         Note 6 - Accrued Expenses - Related Parties         HTML     28K 
                (Tables)                                                         
40: R26         Note 7 - Notes Payable (Tables)                     HTML     37K 
41: R27         Note 9 - Warrant Liability (Tables)                 HTML     31K 
42: R28         Note 11 - Equity Transactions (Tables)              HTML     58K 
43: R29         Note 1 - Organization and Summary of Significant    HTML     52K 
                Accounting Policies (Details)                                    
44: R30         Note 1 - Organization and Summary of Significant    HTML     29K 
                Accounting Policies (Details) - Schedule of                      
                Earnings Per Share, Basic and Diluted                            
45: R31         Note 1 - Organization and Summary of Significant    HTML     31K 
                Accounting Policies (Details) - Schedule of                      
                Deferred Tax Assets and Liabilities                              
46: R32         Note 1 - Organization and Summary of Significant    HTML     35K 
                Accounting Policies (Details) - Schedule of                      
                Effective Income Tax Rate Reconciliation                         
47: R33         Note 1 - Organization and Summary of Significant    HTML     24K 
                Accounting Policies (Details) - Schedule of                      
                Effective Income Tax Rate Reconciliation                         
                (Parentheticals)                                                 
48: R34         Note 2 Inventory (Details)                          HTML     23K 
49: R35         Note 3 - Trademark and Patents (Details)            HTML     38K 
50: R36         Note 3 - Trademark and Patents (Details) -          HTML     32K 
                Schedule of Finite-Lived Intangible Assets                       
51: R37         Note 4 - Accounts Payable - Related Parties         HTML     29K 
                (Details)                                                        
52: R38         NOTE 5 - ACCRUED EXPENSES (Details) - Schedule of   HTML     29K 
                Accrued Liabilities                                              
53: R39         Note 6 - Accrued Expenses - Related Parties         HTML     24K 
                (Details)                                                        
54: R40         Note 6 - Accrued Expenses - Related Parties         HTML     28K 
                (Details) - Schedule of Accrued Liabilities                      
55: R41         NOTE 7 - NOTES PAYABLE (Details) - Schedule of      HTML     41K 
                Debt                                                             
56: R42         Note 7 - Notes Payable (Details) - Schedule of      HTML     73K 
                Debt (Parentheticals)                                            
57: R43         Note 8 - Notes Payable - Related Parties (Details)  HTML     41K 
58: R44         Note 9 - Warrant Liability (Details)                HTML     32K 
59: R45         Note 9 - Warrant Liability (Details) - Fair Value   HTML     31K 
                Measurements, Recurring and Nonrecurring,                        
                Valuation Techniques                                             
60: R46         Note 10 - Commitments and Contingencies (Details)   HTML    158K 
61: R47         Note 11 - Equity Transactions (Details)             HTML    115K 
62: R48         Note 11 - Equity Transactions (Details) - Schedule  HTML     35K 
                of Share-based Payment Award, Stock Options,                     
                Valuation Assumptions                                            
63: R49         Note 11 - Equity Transactions (Details) - Schedule  HTML     54K 
                of Stock Options Roll Forward                                    
64: R50         Note 11 - Equity Transactions (Details) -           HTML     44K 
                Share-based Compensation, Stock Options, Activity                
65: R51         Note 12 - Going Concern (Details)                   HTML     47K 
66: R52         Note 13 - Subsequent Events (Details)               HTML     67K 
68: XML         IDEA XML File -- Filing Summary                      XML    120K 
67: EXCEL       IDEA Workbook of Financial Reports                  XLSX     66K 
 9: EX-101.INS  XBRL Instance -- mzei-20171231                       XML    809K 
11: EX-101.CAL  XBRL Calculations -- mzei-20171231_cal               XML    100K 
12: EX-101.DEF  XBRL Definitions -- mzei-20171231_def                XML    692K 
13: EX-101.LAB  XBRL Labels -- mzei-20171231_lab                     XML    807K 
14: EX-101.PRE  XBRL Presentations -- mzei-20171231_pre              XML    656K 
10: EX-101.SCH  XBRL Schema -- mzei-20171231                         XSD    137K 
69: ZIP         XBRL Zipped Folder -- 0001185185-18-000468-xbrl      Zip    115K 


‘EX-10.23’   —   Material Contract


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 C: 
 
Exhibit 10.23
 

FIRST AMENDMENT TO EQUITY PURCHASE AGREEMENT

THIS FIRST AMENDMENT TO EQUITY PURCHASE AGREEMENT (the “Amendment”), dated as of March 16, 2018, is made and entered into by and among Medizone International, Inc., a Nevada corporation (the “Company”), L2 Capital, LLC, a Kansas limited liability company (“L2”), and SBI Investments LLC, 2014-1, a statutory series of Delaware limited liability company (“SBI”) (together with it permitted assigns, L2 and SBI shall collectively be referred to herein as the “Investor” or “Participating Investors”).
WITNESSETH:
WHEREAS, Seller, L2 and SBI entered into an Equity Purchase and Contribution Agreement dated as of January 31, 2018 (the “Agreement”); and
WHEREAS, the parties hereto now wish to amend certain terms and conditions contained in the Agreement as set forth herein.
NOW THEREFORE, for and in consideration of the premises, the covenants and promises set forth in this Amendment, and other good and valuable consideration, the receipt and the adequacy of which are hereby acknowledged, the parties hereto agree as follows:
1. Amendment to Definition.  The definition of “Purchase Price” in Section 1.1 of the Agreement is hereby deleted in their entirety and replaced with the following:
  “Purchase Price” shall mean 85% of the Market Price on such date on which the Purchase Price is calculated in accordance with the terms and conditions of this Agreement; provided, however, in the event the Market Price on such date is less than $0.01 per share, “Purchase Price” shall mean 80% of the Market Price on such date.
2. Amendment of Section 2.1.  Section 2.1 of the Agreement is hereby deleted in its entirety and replaced with the following:
“Section 2.1 PUTS. Upon the terms and conditions set forth herein (including, without limitation, the provisions of Article VII), the Company shall have the right, but not the obligation, to direct the Participating Investors, by its delivery to the Participating Investors of a Put Notice from time to time, to purchase Put Shares (i) in a minimum amount not less than $20,000.00, and (ii) in a maximum amount of $1,000,000.00; provided that the number of Put Shares issuable pursuant to one (1) Put Notice may not exceed the Maximum Put Shares Quantity. Unless otherwise agreed to in writing by all of the Participating Investors, the amount in the Put Notice shall be allocated pro rata among the Participating Investors based upon the Maximum Commitment Amount of such Participating Investors, unless the Beneficial Ownership Limitation would prevent the Company from selling a Participating Investor (such Participating Investor, a “Disqualified Investor”) additional shares of Common Stock, in which case the pro rata portion of the Aggregate Investment Amount that otherwise would have been allocated to the Disqualified Investor shall be allocated pro rata the among the other Participating Investors based upon the Maximum Commitment Amount of such Participating Investors.  If on the Closing one of the Participating Investors shall fail or refuse to purchase the Put Shares allocated to it, the other Participating Investor shall be obligated to purchase the Put Shares not purchased by the defaulting Participating Investor.”

3. Amendment of Section 7.2(p).  Section 7.2(p) of the Agreement is hereby deleted in its entirety and replaced with “[OMITTED INTENTIONALLY]”.
4. Full Force and Effect.  Except as amended herein, all provisions of the Agreement shall remain unchanged and in full force and effect.
5. Governing Law; Jurisdiction.  This  Agreement shall be governed by and interpreted in accordance with the laws of the State of Kansas without regard to the principles of conflicts of law. Each of the Company and the Investor hereby submits to the exclusive jurisdiction of the United States federal and state courts located in Kansas, County of Johnson, with respect to any dispute arising under the Transaction Documents or the transactions contemplated thereby.
6. Jury Trial Waiver. The Company and the Investor hereby waive a trial by jury in any action, proceeding or counterclaim brought by either of the parties hereto against the other in respect of any matter arising out of or in connection with the Transaction Documents.
7. Counterparts.  This Agreement may be executed in counterparts, each of which will be deemed an original, and all of which together will constitute one and the same instrument.
[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the parties hereto have executed or caused their duly authorized representative to execute this Amendment as of the date first above written.

MEDIZONE INTERNATIONAL, INC.


By:  /s/ David A. Dodd 
Name: David A. Dodd
Title: Chief Executive Officer


L2 CAPITAL, LLC


By:  /s/ Adam Long 
Name: Adam Long
Title: Managing Partner


SBI INVESTMENTS LLC, 2014-1

By:  /s/ Jonathan Juchno 
Name: Jonathan Juchno
Title: Principal




Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/20/18
3/16/18
1/31/188-K
For Period end:12/31/17
 List all Filings 
Top
Filing Submission 0001185185-18-000468   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., Apr. 27, 5:10:12.1pm ET